date:May 09, 2014
nd other income adjusted to exclude share-based compensation expense, increased 3.5 percent to $9.5 million, compared to $9.2 million in the first quarter of 2013.
Net income was $9.7 million, or $0.58 per diluted common share, compared to $4.9 million, or $0.30 per diluted common share in the first quarter of 2013, reflecting a one-time tax benefit related to intercompany dividends.
Our clinically-proven prostate balancing product, Equolibrium, which launched at our US National Convention at t